ADR Cases Could Be Prosecuted Under Kickback Statute – U.S. Atty Sheehan
Executive Summary
The federal anti-kickback statute is broad enough to allow prosecution of pharmaceutical manufacturers for inadequate reporting of adverse events, Philadelphia Assistant U.S. Attorney James Sheehan maintained during a Food & Drug Law Institute meeting Sept. 12 in Washington, D.C
You may also be interested in...
Philadelphia Rx Fraud Investigations Have New Chief; Are SEC Cases Next?
The Philadelphia U.S. Attorney's selection of Virginia Gibson to succeed Jim Sheehan as its Civil Division chief suggests continuity in the office's prescription drug fraud and kickback investigations
Philadelphia Rx Fraud Investigations Have New Chief; Are SEC Cases Next?
The Philadelphia U.S. Attorney's selection of Virginia Gibson to succeed Jim Sheehan as its Civil Division chief suggests continuity in the office's prescription drug fraud and kickback investigations
Abbott ADR Reporting Cited In FDA Warning Letter On Meridia, Norvir, Biaxin
Abbott expects that continued improvements to its Adverse Event Global Information System (AEGIS) will address ADR reporting problems cited in an 1FDA warning letter